Dihydroergotamine Shortage: What Providers and Prescribers Need to Know in 2026

Dihydroergotamine Mesylate (DHE) remains a cornerstone of acute migraine and cluster headache management, particularly for patients with refractory presentations or those requiring infusion-based protocols. However, ongoing supply constraints continue to challenge prescribers and their patients in 2026. This briefing provides an overview of the current shortage landscape, prescribing considerations, and tools to help maintain patient access.

Shortage Timeline and Current Status

Dihydroergotamine Mesylate injection has appeared on the ASHP drug shortage list intermittently since 2022. The shortage stems primarily from manufacturing consolidation — with the discontinuation of the original D.H.E. 45 brand, Hikma Pharmaceuticals became the primary supplier of the generic injectable form (1 mg/mL single-dose ampule).

As of early 2026, Hikma has Dihydroergotamine injection listed as available, but distribution remains uneven. Some hospital and retail pharmacies report consistent access while others experience periodic stockouts. The nasal spray products (Migranal and Trudhesa) have had their own intermittent availability challenges, typically related to insurance-driven demand fluctuations and limited manufacturing capacity.

Prescribing Implications

The supply variability creates several practical challenges for prescribers:

• Infusion center protocols — Facilities using DHE for multi-day infusion protocols (e.g., the Raskin protocol for status migrainosus or medication overuse headache) should proactively confirm supply before scheduling patients. Consider maintaining a small buffer stock where institutional policies allow.
• Outpatient prescriptions — Patients may need to contact multiple pharmacies to fill prescriptions. Advise patients to refill early and consider prescribing a backup acute treatment in case DHE is unavailable.
• Formulation flexibility — When the injectable is unavailable, consider prescribing an alternative delivery system. Trudhesa (nasal spray with POD technology), Brekiya (subcutaneous autoinjector, approved 2025), and Atzumi (nasal powder, approved 2025) all deliver Dihydroergotamine through non-IV routes suitable for home use.

The Evolving Availability Picture

The 2025 approvals of Brekiya and Atzumi represent meaningful additions to the DHE product landscape. Here's how the current formulations compare:

• Generic DHE injection (Hikma) — 1 mg/mL ampule, IV/IM/SC. Lowest cost option. Subject to shortage.
• Migranal nasal spray — 4 mg/mL, 0.5 mg per spray. Established product, moderate cost.
• Trudhesa nasal spray — 0.725 mg per actuation, POD delivery for improved upper nasal deposition. Higher cost (~$4,000+ without insurance); manufacturer copay program available.
• Brekiya autoinjector — 1 mg SC per dose, up to 3 mg/24h. First DHE autoinjector. Convenient for at-home self-administration. Pricing emerging.
• Atzumi nasal powder — Powder formulation may offer more consistent absorption vs. liquid sprays. Newly approved (2025), pricing and formulary placement in development.

Cost and Access Considerations

Cost remains a significant barrier to Dihydroergotamine access for many patients. Key considerations for prescribers:

• Generic injection — Cash price approximately $260-$500 with discount cards. Most formularies cover it, though some plans classify it as non-preferred.
• Brand products — Trudhesa, Brekiya, and Atzumi typically require prior authorization and may have step therapy requirements (trial of generic DHE or triptans first).
• Savings programs — The Trudhesa Direct Savings Program offers eligible commercially insured patients $0 copay. Manufacturer assistance for Brekiya is being established. Prescription Hope offers Migranal for $70/month for qualifying patients.

Tools and Resources for Your Practice

Several resources can help you and your patients navigate the DHE shortage:

• Medfinder for Providers — A real-time pharmacy stock checker that helps patients locate Dihydroergotamine at nearby pharmacies. Direct patients to Medfinder.com or use the provider portal to assist with searches.
• ASHP Drug Shortage Resource Center — Monitor current shortage status and estimated resupply dates at ashp.org.
• Manufacturer support lines — Trudhesa (1-800-589-0841) for copay assistance and prior authorization support. Zevra Therapeutics for Brekiya access questions.
• Patient assistance programs — NeedyMeds.org and RxAssist.org can help identify financial assistance for uninsured or underinsured patients.

Looking Ahead

The 2025 approvals of Brekiya and Atzumi are encouraging signs for the DHE market. As these products gain formulary placement and manufacturers ramp up production, the overall supply of Dihydroergotamine should improve. However, the generic injectable market remains vulnerable to single-source disruptions.

For the near term, providers should maintain awareness of multiple DHE formulations, keep alternative treatment protocols ready, and proactively communicate with patients about availability challenges. Prescribing flexibility — including willingness to switch between formulations based on availability — will be essential for continuity of care.

Final Thoughts

The Dihydroergotamine shortage underscores the fragility of single-source generic supply chains. As prescribers, staying informed about the current landscape — including new formulations, savings programs, and pharmacy-level availability tools — directly impacts our ability to serve patients who depend on DHE. Visit Medfinder for Providers for real-time availability data and additional resources.